—— Company profile ——

Ongke Biomedical Technology (Suzhou) Co., Ltd was established in Suzhou in November 2010, is a Sino-foreign joint venture dedicated to the development of high-tech biomedical professional in the diagnosis and treatment of urinary system diseases. The scientific research team of the company is led by famous scientists at home and abroad, and many Chinese and foreign experts who have been active in the international cancer research field for a long time.

The first phase of the company's products are mainly novel, non-invasive, humoral based prostatitis detection reagents, while developing tumor specific detection platforms and reagents.

The company has global original products: prostatic body leakage protein detection kit (enzyme linked immunoassay) and prostatic body leakage protein detection kit (colloidal gold method), with global originality, filling the gap in the global in vitro diagnosis of chronic prostatitis. The kit is a simple and reliable method for the diagnosis of non-invasive prostatitis based on urine molecular test. It can be used for general clinical reference and general survey of young and middle-aged men.

At the same time, another global original product, a kit for early diagnosis and prognosis of prostate cancer based on urine detection of delta-catenin level, is also completing clinical trials and registration certificate application stage.

In order to accelerate the use of innovative technologies for clinical applications, Encore Medical will also continue to expand the GMP base, with the goal of becoming a new biomedical center. The aim of Aoke Medicine is: to take the interests of patients as the center, to quickly push products into the clinic, early screening, early diagnosis, early treatment, and improve the quality of life of patients.